Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Open Access

Correction

Correction: Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer

  • The PLOS ONE Staff
  • Article
  • Metrics
  • Comments
  • Media Coverage

Notice of republication

This article was republished on April 8, 2021, to correct errors in the Data Availability Statement that were introduced during the typesetting process. The publisher apologizes for the errors. Please download this article again to view the correct version. The originally published, uncorrected article and the republished, corrected articles are provided here for reference.

Supporting information

S1 File. Originally published, uncorrected article.

https://doi.org/10.1371/journal.pone.0251671.s001

(PDF)

S2 File. Republished, corrected article.

https://doi.org/10.1371/journal.pone.0251671.s002

(PDF)

Reference

  1. 1. Frame S, Saladino C, MacKay C, Atrash B, Sheldrake P, McDonald E, et al. (2020) Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer. PLoS ONE 15(7): e0234103. https://doi.org/10.1371/journal.pone.0234103 pmid:32645016

Citation: The PLOS ONE Staff (2021) Correction: Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer. PLoS ONE 16(5): e0251671. https://doi.org/10.1371/journal.pone.0251671

Published: May 6, 2021

Copyright: © 2021 The PLOS ONE Staff . This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.